Bimekizumab Superior to Cosentyx® in Achieving Complete Psoriasis Skin Clearance.

Brussels, Belgium – 24th July 2020, 7:00 AM CEST – Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive results from the Phase 3b BE RADIANT study, a direct comparison of the investigational IL-17A and IL-17F inhibitor, bimekizumab, to the IL-17A inhibitor, Cosentyx® (secukinumab) in the treatment of adult patients with moderate-to-severe plaque psoriasis. 1 BE RADIANT is the first head-to-head study comparing anti-IL-17 treatments, and the first study to demonstrate superiority to secukinumab for complete skin clearance at both weeks...